2 reports of this reaction
1.9% of all SODIUM SULFACETAMIDE, SULFUR reports
#6 most reported adverse reaction
INJECTION SITE SWELLING is the #6 most commonly reported adverse reaction for SODIUM SULFACETAMIDE, SULFUR, manufactured by Acella Pharmaceuticals, LLC. There are 2 FDA adverse event reports linking SODIUM SULFACETAMIDE, SULFUR to INJECTION SITE SWELLING. This represents approximately 1.9% of all 106 adverse event reports for this drug.
Patients taking SODIUM SULFACETAMIDE, SULFUR who experience injection site swelling should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INJECTION SITE SWELLING is a less commonly reported adverse event for SODIUM SULFACETAMIDE, SULFUR, but still significant enough to appear in the safety profile.
In addition to injection site swelling, the following adverse reactions have been reported for SODIUM SULFACETAMIDE, SULFUR:
The following drugs have also been linked to injection site swelling in FDA adverse event reports:
INJECTION SITE SWELLING has been reported as an adverse event in 2 FDA reports for SODIUM SULFACETAMIDE, SULFUR. This does not prove causation, but indicates an association observed in post-market surveillance data.
INJECTION SITE SWELLING accounts for approximately 1.9% of all adverse event reports for SODIUM SULFACETAMIDE, SULFUR, making it a notable side effect.
If you experience injection site swelling while taking SODIUM SULFACETAMIDE, SULFUR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.